CLINDAMYCIN PHOSPHATE- clindamycin phosphate lotion 
CLINDAMYCIN PHOSPHATE- clindamycin phosphate solution 
CLINDAMYCIN PHOSPHATE- clindamycin phosphate gel 
E. Fougera & Co. a division of Fougera Pharmaceuticals Inc.

----------

Clindamycin Phosphate Topical Solution USP, 1%,
Clindamycin Phosphate Gel USP, 1%,
Clindamycin Phosphate Lotion
(Clindamycin Phosphate Topical Suspension USP, 1%)

Rx only

For External Use.

DESCRIPTION

Clindamycin Phosphate Topical Solution and Clindamycin Phosphate Lotion (Clindamycin Phosphate Topical Suspension USP, 1%) contain clindamycin phosphate, USP, at a concentration equivalent to 10 mg clindamycin per milliliter. Clindamycin Phosphate Gel contains clindamycin phosphate, USP, at a concentration equivalent to 10 mg clindamycin per gram. Clindamycin phosphate is a water soluble ester of the semi-synthetic antibiotic produced by a 7(S)-chloro-substitution of the 7(R)-hydroxyl group of the parent antibiotic lincomycin.

The solution contains isopropyl alcohol 50% v/v, propylene glycol, and purified water.

The gel contains allantoin, carbomer 974P, methylparaben, polyethylene glycol 400, propylene glycol, sodium hydroxide, and purified water.

The lotion contains cetostearyl alcohol (2.5%); glycerin; glyceryl stearate SE (with potassium monostearate); isostearyl alcohol (2.5%); methylparaben (0.3%); sodium lauroyl sarcosinate; stearic acid; and purified water.

The structural formula is represented below:

structural formula

The chemical name for clindamycin phosphate is Methyl 7-chloro-6,7,8-trideoxy-6-(1-methyl-trans-4-propyl-L-2-pyrrolidinecarboxamido)-1-thio-L-threo-α-D-galacto-octopyranoside 2-(dihydrogen phosphate).

CLINICAL PHARMACOLOGY

Although clindamycin phosphate is inactive in vitro, rapid in vivo hydrolysis converts this compound to the antibacterially active clindamycin.

Cross resistance has been demonstrated between clindamycin and lincomycin.

Antagonism has been demonstrated between clindamycin and erythromycin.

Following multiple topical applications of clindamycin phosphate at a concentration equivalent to 10 mg clindamycin per mL in an isopropyl alcohol and water solution, very low levels of clindamycin are present in the serum (0 to 3 ng/mL) and less than 0.2% of the dose is recovered in urine as clindamycin.

Clindamycin activity has been demonstrated in comedones from acne patients. The mean concentration of antibiotic activity in extracted comedones after application of Clindamycin Phosphate Topical Solution for 4 weeks was 597 mcg/g of comedonal material (range 0 to 1,490). Clindamycin in vitro inhibits all Propionibacterium acnes cultures tested (MICs 0.4 mcg/mL). Free fatty acids on the skin surface have been decreased from approximately 14% to 2% following application of clindamycin.

INDICATIONS AND USAGE

Clindamycin Phosphate Topical Solution, Clindamycin Phosphate Gel, and Clindamycin Phosphate Lotion are indicated in the treatment of acne vulgaris. In view of the potential for diarrhea, bloody diarrhea and pseudomembranous colitis, the physician should consider whether other agents are more appropriate. (See CONTRAINDICATIONS, WARNINGS and ADVERSE REACTIONS.)

CONTRAINDICATIONS

Clindamycin Phosphate Topical Solution, Clindamycin Phosphate Gel, and Clindamycin Phosphate Lotion are contraindicated in individuals with a history of hypersensitivity to preparations containing clindamycin or lincomycin, a history of regional enteritis or ulcerative colitis, or a history of antibiotic-associated colitis.

WARNINGS

Orally and parenterally administered clindamycin has been associated with severe colitis which may result in patient death. Use of the topical formulation of clindamycin results in absorption of the antibiotic from the skin surface. Diarrhea, bloody diarrhea, and colitis (including pseudomembranous colitis) have been reported with the use of topical and systemic clindamycin.

Studies indicate a toxin(s) produced by clostridia is one primary cause of antibiotic-associated colitis. The colitis is usually characterized by severe persistent diarrhea and severe abdominal cramps and may be associated with the passage of blood and mucus. Endoscopic examination may reveal pseudomembranous colitis. Stool culture for Clostridium difficile and stool assay for C. difficile toxin may be helpful diagnostically.

When significant diarrhea occurs, the drug should be discontinued. Large bowel endoscopy should be considered to establish a definitive diagnosis in cases of severe diarrhea.

Antiperistaltic agents such as opiates and diphenoxylate with atropine may prolong and/or worsen the condition. Vancomycin has been found to be effective in the treatment of antibiotic-associated pseudomembranous colitis produced by Clostridium difficile. The usual adult dosage is 500 mg to 2 grams of vancomycin orally per day in three to four divided doses administered for 7 to 10 days.

Cholestyramine or colestipol resins bind vancomycin in vitro. If both a resin and vancomycin are to be administered concurrently, it may be advisable to separate the time of administration of each drug.

Diarrhea, colitis, and pseudomembranous colitis have been observed to begin up to several weeks following cessation of oral and parenteral therapy with clindamycin.

PRECAUTIONS

General: Clindamycin Phosphate Topical Solution contains an alcohol base which will cause burning and irritation of the eye. In the event of accidental contact with sensitive surfaces (eye, abraded skin, mucous membranes), bathe with copious amounts of cool tap water. The solution has an unpleasant taste and caution should be exercised when applying medication around the mouth.

Clindamycin phosphate should be prescribed with caution in atopic individuals.

Drug Interactions: Clindamycin has been shown to have neuromuscular blocking properties that may enhance the action of other neuromuscular blocking agents. Therefore it should be used with caution in patients receiving such agents.

Pregnancy:Teratogenic Effects—Pregnancy Category B. In clinical trials with pregnant women, the systemic administration of clindamycin during the second and third trimesters has not been associated with an increased frequency of congenital abnormalities. There are no adequate studies in pregnant women during the first trimester of pregnancy. Clindamycin should be used during the first trimester of pregnancy only if clearly needed.

Nursing Mothers: It is not known whether clindamycin is excreted in human milk following use of clindamycin phosphate. However, orally and parenterally administered clindamycin has been reported to appear in breast milk. Because of the potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

Pediatric Use: Safety and effectiveness in pediatric patients under the age of 12 have not been established.

Geriatric Use: Clinical studies for topical Clindamycin products did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients.

ADVERSE REACTIONS

In 18 clinical studies of various formulations of clindamycin phosphate using placebo vehicle and/or active comparator drugs as controls, patients experienced a number of treatment emergent adverse dermatologic events [see table below].

Number of Patients Reporting Events
# not recorded
* of 126 subjects

Treatment Emergent
Adverse Event

Solution

Gel

Lotion

n=553

(%)

n=148

(%)

n=160

(%)

Burning

62

(11)

15

(10)

17

(11)

Itching

36

( 7)

15

(10)

17

(11)

Burning/Itching

60

(11)

#

( –)

#

( –)

Dryness

105

(19)

34

(23)

29

(18)

Erythema

86

(16)

10

( 7)

22

(14)

Oiliness/Oily Skin

8

( 1)

26

(18)

12*

(10)

Peeling

61

(11)

#

( –)

11

( 7)

Orally and parenterally administered clindamycin has been associated with severe colitis which may end fatally.

Cases of diarrhea, bloody diarrhea and colitis (including pseudomembranous colitis) have been reported as adverse reactions in patients treated with oral and parenteral formulations of clindamycin and rarely with topical clindamycin. (see WARNINGS.)

Abdominal pain and gastrointestinal disturbances as well as gram-negative folliculitis have also been reported in association with the use of topical formulations of clindamycin.

OVERDOSAGE

Topically applied clindamycin phosphate can be absorbed in sufficient amounts to produce systemic effects. (see WARNINGS.)

DOSAGE AND ADMINISTRATION

Apply a thin film of Clindamycin Phosphate Topical Solution, Clindamycin Phosphate Lotion, or Clindamycin Phosphate Gel twice daily to affected area.

Lotion: Shake well immediately before using.

Keep all liquid dosage forms in containers tightly closed.

HOW SUPPLIED

Clindamycin Phosphate Topical Solution, USP 1% containing clindamycin phosphate equivalent to 10 mg clindamycin per milliliter is available in the following sizes:

30 mL applicator bottle NDC 0168-0201-30
60 mL applicator bottle NDC 0168-0201-60

Clindamycin Phosphate Gel, USP 1% containing clindamycin phosphate equivalent to 10 mg clindamycin per gram is available in the following sizes:

30 gram tube NDC 0168-0202-30
60 gram tube NDC 0168-0202-60

Clindamycin Phosphate Lotion (Clindamycin Phosphate Topical Suspension, USP 1%) containing clindamycin phosphate equivalent to 10 mg clindamycin per milliliter is available in the following size:

60 mL bottle NDC 0168-0203-60

Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature]. Protect from freezing.

Fougera
PHARMACEUTICALS INC.

E. FOUGERA & CO.
A division of Fougera Pharmaceuticals Inc.
MELVILLE, NEW YORK 11747

I201C/IF201C
R07/14
#90

PACKAGE LABEL – PRINCIPAL DISPLAY PANEL – 60 mL CONTAINER

NDC 0168-0203-60

Fougera ®

CLINDAMYCIN
PHOSPHATE LOTION
(Clindamycin Phosphate

Topical Suspension
USP, 1%)

Equivalent to 1% (10 mg/mL)
clindamycin

FOR TOPICAL USE ONLY.
60 mL

Rx only

E. FOUGERA & CO.
A division of
Fougera Pharmaceuticals Inc.
Melville, New York 11747

lotion 60ml label

PACKAGE LABEL – PRINCIPAL DISPLAY PANEL – 60 mL CARTON

NDC 0168-0203-60

Fougera ®

CLINDAMYCIN
PHOSPHATE
LOTION
(Clindamycin
Phosphate Topical
Suspension

USP, 1%)

Equivalent to 1%
(10 mg/mL) clindamycin

FOR TOPICAL USE ONLY.

60 mL

Rx only

E. FOUGERA & CO.
A division of
Fougera Pharmaceuticals Inc.
Melville, New York 11747

lotion 60ml carton

PACKAGE LABEL – PRINCIPAL DISPLAY PANEL – 60 mL CONTAINER

NDC 0168-0201-60

Fougera ®

CLINDAMYCIN
PHOSPHATE
Topical Solution USP, 1%
Equivalent to 1%
(10 mg/mL) clindamycin
WARNING: Keep out
of reach of children.

For Topical Use Only.

Rx only
60 mL

E. FOUGERA & CO.
A division of
Fougera Pharmaceuticals Inc.
Melville, New York 11747

ts 60ml label

PACKAGE LABEL – PRINCIPAL DISPLAY PANEL – 60 mL CARTON

NDC 0168-0201-60

Fougera ®

CLINDAMYCIN
PHOSPHATE
Topical Solution
USP, 1%

Equivalent to 1%
(10 mg/mL) clindamycin

For Topical Use Only.

60 mL

Rx only

E. FOUGERA & CO.
A division of
Fougera Pharmaceuticals Inc.
Melville, New York 11747

ts 60ml carton

PACKAGE LABEL – PRINCIPAL DISPLAY PANEL – 30 G CONTAINER

NDC 0168-0202-30

Fougera ®

CLINDAMYCIN
PHOSPHATE GEL USP, 1%

equivalent to 1% clindamycin

For Topical Use Only.

Rx only

NET WT 30 grams

gel 30g label

PACKAGE LABEL – PRINCIPAL DISPLAY PANEL – 30 G CARTON

NDC 0168-0202-30

Rx only

Fougera ®

CLINDAMYCIN
PHOSPHATE GEL USP, 1%

equivalent to 1% clindamycin
For Topical Use Only.

FOR EXTERNAL USE ONLY.
AVOID CONTACT WITH EYES.
WARNING: Keep out of
reach of children.

NET WT 30 grams

gel 30g carton
CLINDAMYCIN PHOSPHATE 
clindamycin phosphate lotion
Product Information
Product TypeHUMAN PRESCRIPTION DRUG LABELItem Code (Source)NDC:0168-0203
Route of AdministrationTOPICALDEA Schedule    
Active Ingredient/Active Moiety
Ingredient NameBasis of StrengthStrength
CLINDAMYCIN PHOSPHATE (CLINDAMYCIN) CLINDAMYCIN10 mg  in 1 mL
Inactive Ingredients
Ingredient NameStrength
CETOSTEARYL ALCOHOL 
GLYCERIN 
GLYCERYL MONOSTEARATE 
ISOSTEARYL ALCOHOL 
METHYLPARABEN 
SODIUM LAUROYL SARCOSINATE 
STEARIC ACID 
WATER 
Packaging
#Item CodePackage DescriptionMarketing Start DateMarketing End Date
1NDC:0168-0203-601 in 1 CARTON
160 mL in 1 BOTTLE
Marketing Information
Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
ANDAANDA06506701/31/2002
CLINDAMYCIN PHOSPHATE 
clindamycin phosphate solution
Product Information
Product TypeHUMAN PRESCRIPTION DRUG LABELItem Code (Source)NDC:0168-0201
Route of AdministrationTOPICALDEA Schedule    
Active Ingredient/Active Moiety
Ingredient NameBasis of StrengthStrength
CLINDAMYCIN PHOSPHATE (CLINDAMYCIN) CLINDAMYCIN10 mg  in 1 mL
Inactive Ingredients
Ingredient NameStrength
ISOPROPYL ALCOHOL 
PROPYLENE GLYCOL 
WATER 
Packaging
#Item CodePackage DescriptionMarketing Start DateMarketing End Date
1NDC:0168-0201-301 in 1 CARTON
130 mL in 1 BOTTLE
2NDC:0168-0201-601 in 1 CARTON
260 mL in 1 BOTTLE
Marketing Information
Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
ANDAANDA06415906/05/1997
CLINDAMYCIN PHOSPHATE 
clindamycin phosphate gel
Product Information
Product TypeHUMAN PRESCRIPTION DRUG LABELItem Code (Source)NDC:0168-0202
Route of AdministrationTOPICALDEA Schedule    
Active Ingredient/Active Moiety
Ingredient NameBasis of StrengthStrength
CLINDAMYCIN PHOSPHATE (CLINDAMYCIN) CLINDAMYCIN10 mg  in 1 g
Inactive Ingredients
Ingredient NameStrength
ALLANTOIN 
METHYLPARABEN 
POLYETHYLENE GLYCOL 400 
PROPYLENE GLYCOL 
SODIUM HYDROXIDE 
WATER 
CARBOMER HOMOPOLYMER TYPE B (ALLYL PENTAERYTHRITOL CROSSLINKED) 
Packaging
#Item CodePackage DescriptionMarketing Start DateMarketing End Date
1NDC:0168-0202-301 in 1 CARTON
130 g in 1 TUBE
2NDC:0168-0202-601 in 1 CARTON
260 g in 1 TUBE
Marketing Information
Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
ANDAANDA06416001/28/2010
Labeler - E. Fougera & Co. a division of Fougera Pharmaceuticals Inc. (043838424)

Revised: 8/2014
Document Id: e0752517-f24c-4706-a832-10cdc9c4fc83
Set id: 62a2019f-7410-4251-95ed-181925ade6e4
Version: 8
Effective Time: 20140812
 
E. Fougera & Co. a division of Fougera Pharmaceuticals Inc.